Soleno Therapeutics Investors Seek Lead in Class Action Lawsuit

Hagens Berman law firm reminds investors of upcoming lead plaintiff deadline in securities class action against Soleno Therapeutics.

Apr. 9, 2026 at 3:37pm

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up image of heavy, industrial pharmaceutical manufacturing equipment and machinery, conveying the complex financial and regulatory infrastructure involved in drug development and commercialization.An extreme close-up of the intricate machinery behind the pharmaceutical industry exposes the complex financial and regulatory landscape that drug companies must navigate.Gainesville Today

National shareholder rights law firm Hagens Berman is reminding investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm is urging investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 and suffered significant losses to submit their claims.

Why it matters

The class action lawsuit alleges that Soleno misrepresented the safety, efficacy, and commercial viability of its flagship product VYKAT XR (DCCR) for the treatment of Prader-Willi syndrome. The complaint claims the company downplayed safety concerns, used questionable data, and inflated launch metrics to maintain an inflated stock price.

The details

The Soleno class action focuses on the company's repeated assurances regarding VYKAT XR (DCCR), including allegations that Soleno failed to disclose significant evidence of safety concerns, data integrity issues in its clinical trials, and inflated launch metrics. The complaint alleges these issues were eventually revealed through an activist short seller report and the company's own financial disclosures, leading to significant stock price declines.

  • The Class Period is from March 26, 2025 to November 4, 2025.
  • The lead plaintiff deadline is May 5, 2026.
  • On August 15, 2025, an activist short seller report triggered an immediate double-digit decline in Soleno's stock price.
  • On November 4, 2025, Soleno reported Q3 2025 results, acknowledging a disruption in DCCR's launch and a lower number of patient start forms, causing the stock to plummet 27% in a single day.

The players

Hagens Berman

A global plaintiffs' rights complex litigation firm focusing on corporate accountability, representing investors, whistleblowers, workers, and consumers in cases achieving real results for those harmed by corporate negligence and wrongdoing.

Reed Kathrein

The Hagens Berman partner leading the firm's investigation of the alleged claims against Soleno Therapeutics.

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Scorpion Capital

An activist short seller that published a report titled "Russian Roulette With Prader-Willi Children" detailing alleged widespread adverse patient reactions and investigator skepticism regarding Soleno's clinical trials.

City of Pontiac Police & Fire Ret. Sys.

The lead plaintiff in the securities class action lawsuit against Soleno Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Our investigation centers on the complaint's claims that Soleno allegedly bypassed critical safety protocols and used questionable metrics to maintain an inflated stock price.”

— Reed Kathrein, Hagens Berman partner

What’s next

The lead plaintiff deadline in the Soleno Therapeutics securities class action is May 5, 2026. Investors who purchased Soleno common stock during the Class Period and suffered significant losses are encouraged to submit their claims before the deadline to potentially serve as lead plaintiff.

The takeaway

This case highlights the importance of transparency and integrity in the biopharmaceutical industry, as allegations of concealed safety risks, data integrity issues, and inflated metrics can have significant consequences for investors. The upcoming lead plaintiff deadline provides an opportunity for affected Soleno shareholders to potentially lead the class action and seek accountability.